CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), has signed a national agreement with Humana (HUM), effective October 29, covering approximately 16M people throughout the United States, to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test. This brings CNSide CSF TCE LDT total policy coverage to 67M people.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Gains Nasdaq Extension for Compliance
- Plus receives additional extension to regain compliance with Nasdasq
- Plus Therapeutics highlights ReSPECT-LM trial results at SITC meeting
- Buy Rating for Plus Therapeutics: Growth Potential Driven by CNSide Launch and Strategic Positioning
- Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright